Ethosuximide
Overview
Ethosuximide is antiepileptic agent. It was introduced in 1960 as the third of three marketed succinimides. its origin is in the cyclic ureide structure. It has a considerable efficasy against pentylenetetrazol seizures and was introduced as a 'pure petit mal' drug. its popularity continues, based on its safety and efficasy. its role as the first choice anti-absence drug remains undiminished, in part because of the idiosyncratic hepatotoxicity of the alternative drug, valproic acid. Ethosuximide is administered orally.
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Oral absorption of Ethosuximide is found to be 97% ±2. Volume of distribution is found to be 0.7 l/kg and plasma protien binding is negligible. Presystemic metabolism is noted to be 0.00255% ±0.00155 and metabolism is reported hepatic. Renal Excretion accounts for 17-38% and plasma half life is 53-56 hr.
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Reserpine's dosage details are as follows:
Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
14.285 to 21.428 mg/kg | 18 (17.8565) | 24 hourly | PO | Maintenance, As Required |
750 to 1500 mg/d | 1100 (1125) | 24 hourly | PO | Initially for a week |
Paedriatic Dosage (20kg)
|
12.5 to 25 mg/kg | 19 (18.75) | 12 hourly | Oral | Start with low doses, and then Gradually Increase |
Neonatal Dosage (3kg)
|
| | | | Not indicated in this age group |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Caps, Syrup
Store in a well closed container, Below 30°C.
Back to top
Interference in Pathology
- Urinanalysis
- Liver Function Test (LFT)
Back to top
Brands / Trade Names of
Reserpine
Back to top
Previous Drug Generic - Next Drug Generic